scispace - formally typeset
J

Julia D. Ransohoff

Researcher at Stanford University

Publications -  18
Citations -  1423

Julia D. Ransohoff is an academic researcher from Stanford University. The author has contributed to research in topics: Cellular differentiation & Stem-cell therapy. The author has an hindex of 10, co-authored 16 publications receiving 1020 citations. Previous affiliations of Julia D. Ransohoff include Cardiovascular Institute of the South.

Papers
More filters
Journal ArticleDOI

The functions and unique features of long intergenic non-coding RNA.

TL;DR: Long intergenic non-coding RNA genes have diverse features that distinguish them from mRNA-encoding genes and exercise functions such as remodelling chromatin and genome architecture, RNA stabilization and transcription regulation, including enhancer-associated activity.
Journal ArticleDOI

Short-term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem Cells

TL;DR: A short-term immunosuppressive approach capable of inducing engraftment of transplanted ESCs and iPSCs is described, providing a significant improvement in the mechanistic understanding of the critical role costimulatory molecules play in leukocyte activation.
Journal ArticleDOI

Immunogenicity of Pluripotent Stem Cells and Their Derivatives

TL;DR: This approach to overcome immunologic barriers to stem cell therapy can take advantage of the validated knowledge acquired from decades of hematopoietic stem cell transplantation and develop safe, effective strategies to bypass them.
Journal ArticleDOI

CALML5 is a ZNF750- and TINCR-induced protein that binds stratifin to regulate epidermal differentiation.

TL;DR: A ZNF750-TINCR-CALML5-SFN network is thus essential for epidermal differentiation and interaction of SFN to some of its binding partners is identified.
Journal ArticleDOI

In Vivo Functional and Transcriptional Profiling of Bone Marrow Stem Cells After Transplantation Into Ischemic Myocardium

TL;DR: The data suggest that BMMC therapy, in its present iteration, may be less efficacious than once thought and additional refinement of existing cell delivery protocols should be considered to induce better therapeutic efficacy.